Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab phase III trial in acquired thrombotic thrombocytopenic purpura
2015-001098-42Phase 3Completed
- Sponsor
- Ablynx
- Start
- Jul 2015
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Ablynx. Started Jul 2015; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2015-001098-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001098-42.